280 related articles for article (PubMed ID: 8823340)
1. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
Gurney H
J Clin Oncol; 1996 Sep; 14(9):2590-611. PubMed ID: 8823340
[TBL] [Abstract][Full Text] [Related]
2. Dose calculation of anticancer drugs.
Gao B; Klumpen HJ; Gurney H
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1307-19. PubMed ID: 18798700
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
4. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
[TBL] [Abstract][Full Text] [Related]
5. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.
Kouno T; Katsumata N; Mukai H; Ando M; Watanabe T
Jpn J Clin Oncol; 2003 Jun; 33(6):309-13. PubMed ID: 12913086
[TBL] [Abstract][Full Text] [Related]
6. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
[TBL] [Abstract][Full Text] [Related]
7. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
Felici A; Verweij J; Sparreboom A
Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683
[TBL] [Abstract][Full Text] [Related]
8. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
Chatelut E; White-Koning ML; Mathijssen RH; Puisset F; Baker SD; Sparreboom A
Br J Cancer; 2012 Sep; 107(7):1100-6. PubMed ID: 22929884
[TBL] [Abstract][Full Text] [Related]
9. Body surface area as a determinant of pharmacokinetics and drug dosing.
Sawyer M; Ratain MJ
Invest New Drugs; 2001 May; 19(2):171-7. PubMed ID: 11392451
[TBL] [Abstract][Full Text] [Related]
10. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
11. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
12. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
[TBL] [Abstract][Full Text] [Related]
13. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
14. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
15. Body surface area estimation in children using weight alone: application in paediatric oncology.
Sharkey I; Boddy AV; Wallace H; Mycroft J; Hollis R; Picton S;
Br J Cancer; 2001 Jul; 85(1):23-8. PubMed ID: 11437397
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Gurney HP; Ackland S; Gebski V; Farrell G
J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.
Kaestner SA; Sewell GJ
Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):23-37. PubMed ID: 17305252
[TBL] [Abstract][Full Text] [Related]
19. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
20. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
Erku D; Schneider J; Scuffham P
Pharmacol Res Perspect; 2021 Oct; 9(5):e00862. PubMed ID: 34546005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
